Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
基本信息
- 批准号:8692634
- 负责人:
- 金额:$ 31.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-15 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:A-Form DNAAddressAffectAffinityBacillus (bacterium)BacteriaBacterial GenesBacterial InfectionsBacterial PhysiologyBindingBinding SitesBioinformaticsCarbonCessation of lifeConsensus SequenceDNADNA BindingDNA SequenceDataDevelopmentDiseaseEatingEnvironmentFutureGene ExpressionGene Expression ProfileGene Expression ProfilingGene Expression RegulationGenesGoalsGram-Positive BacteriaGrowthHistidineHumanIn VitroInfectionInvestigationLaboratoriesMetabolicMethodsModelingMolecular ProfilingMusMuscleMutationMyositisNatureNecrotizing fasciitisPathogenesisPathway interactionsPharyngeal structurePharyngitisPhosphoproteinsPhosphorylase KinasePhysiologicalPreventive InterventionProductionProteinsRecombinantsResearchResponse ElementsRoleSerineSerotypingSiteSourceStimulusStreptococcal InfectionsStreptococcus pyogenesTestingTranscriptUnited StatesVirulenceVirulence Factorsbasedefined contributiondesigngenetic regulatory proteinin vivoinnovationinsightmouse modelmultiple myeloma M Proteinmutantnovelnovel therapeutic interventionpathogenpathogenic bacteriaresponse
项目摘要
DESCRIPTION (provided by applicant): Infections by Gram-positive bacteria cause tens of thousands of deaths in the United States each year. The transcriptional regulator catabolite control protein A (CcpA) has recently been found to influence the virulence gene expression profile during growth in standard laboratory medium of numerous Gram-positive pathogens including group A Streptococcus (GAS). CcpA was originally identified in Bacillus species where it binds DNA sequences termed catabolite response element (cre) sites in conjunction with its co-factor histidine-containing phosphoprotein phosphorylated at serine residue 46 (HPr-Ser46-P). Orthologues of CcpA, HPr, and the kinase/phosphorylase that regulates HPr phosphorlyation status (HPrK/P) are present in all major Gram- positive human pathogens, and there are accumulating data suggesting that the CcpA-(HPr-Ser46-P)-HPrK/P axis contributes to the infectivity of diverse bacterial species. The long term goals of this project are to clearly define how the CcpA-(HPr-Ser46-P)-HPrK/P axis contributes to GAS virulence and to ascertain mechanisms by which CcpA influences gene expression during infection. The specific aims of this proposal have been designed to test hypotheses arising from preliminary data demonstrating that: 1) Inactivation of CcpA altered GAS gene expression during infection in mouse muscle; 2) Inactivation of CcpA decreased GAS virulence in a mouse myositis model; 3) Mutation of the central CpG of a GAS cre site decreased CcpA-(HPr-Ser46-P) DNA binding affinity; and 4) CcpA influenced gene expression under conditions in which HPr-Ser46-P levels are low or absent. In aim 1, gene expression analysis of wild-type and CcpA-inactivated GAS strains will be performed in multiple mouse models of infection to test the hypothesis that CcpA is a key virulence factor regulator during GAS infection. In aim 2, the virulence of CcpA isogenic mutant strains derived from different M protein serotype parental strains will be compared to their parental wild-type strains in various mouse models of infection to test the hypothesis that CcpA positively contributes to the infectivity of GAS strains of multiple M protein serotypes. In aim 3, a combination of in vitro and in vivo methods will be used to test the hypothesis that the central cre site CpG is critical for the effect of CcpA on GAS gene expression. In aim 4, the gene expression profiles of CcpA and HPr-Ser46-P inactivated strains will be compared under different metabolic conditions to test the hypothesis that CcpA can affect GAS gene expression in the absence of HPr-Ser46-P. The highly conserved nature of the CcpA-(HPr-Ser46-P)-HPrK/P axis amongst major Gram-positive bacterial pathogens means that the successful completion of the proposed research may generate new insights into disease pathogenesis that are relevant to a broad array of pathogenic bacteria. Such information could form the basis for the development of novel therapeutic or preventive interventions.
描述(由申请人提供):革兰氏阳性菌感染每年在美国造成数万人死亡。最近发现转录调节因子分解代谢物控制蛋白A(CcpA)影响许多革兰氏阳性病原体(包括A组链球菌(GAS))在标准实验室培养基中生长期间的毒力基因表达谱。CcpA最初在芽孢杆菌属物种中被鉴定,其中它结合称为分解代谢物反应元件(cre)位点的DNA序列,连同其辅因子含组氨酸的在丝氨酸残基46处磷酸化的磷蛋白(HPr-Ser 46-P)。CcpA、HPr和调节HPr磷酸化状态的激酶/磷酸化酶(HPrK/P)的直向同源物存在于所有主要的革兰氏阳性人类病原体中,并且有积累的数据表明CcpA-(HPr-Ser 46-P)-HPrK/P轴有助于不同细菌物种的感染性。该项目的长期目标是明确定义CcpA-(HPr-Ser 46-P)-HPrK/P轴如何影响GAS毒力,并确定CcpA在感染过程中影响基因表达的机制。该提议的具体目的是为了检验由初步数据产生的假设,这些数据表明:1)在小鼠肌肉中感染期间,CcpA的失活改变了GAS基因表达; 2)在小鼠肌炎模型中,CcpA的失活降低了GAS毒力; 3)GAS cre位点的中心CpG的突变降低了CcpA的表达。(HPr-Ser 46-P)DNA结合亲和力;和4)在HPr-Ser 46-P水平低或不存在的条件下,CcpA影响基因表达。在目标1中,将在多种小鼠感染模型中进行野生型和CcpA灭活GAS菌株的基因表达分析,以检验CcpA是GAS感染期间关键毒力因子调节剂的假设。在目的2中,将在各种小鼠感染模型中将源自不同M蛋白血清型亲本菌株的CcpA同基因突变菌株的毒力与其亲本野生型菌株进行比较,以检验CcpA对多种M蛋白血清型的GAS菌株的感染性有积极贡献的假设。在目标3中,将使用体外和体内方法的组合来检验中心cre位点CpG对于CcpA对GAS基因表达的影响是关键的假设。在目标4中,将在不同的代谢条件下比较CcpA和HPr-Ser 46-P失活菌株的基因表达谱,以检验CcpA在HPr-Ser 46-P不存在的情况下可以影响GAS基因表达的假设。(HPr-Ser 46-P)-HPrK/P轴在主要革兰氏之间-阳性细菌病原体意味着拟议研究的成功完成可能会对疾病发病机制产生新的见解,这些疾病发病机制与广泛的病原菌有关。这些信息可以成为开发新的治疗或预防干预措施的基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SAMUEL A SHELBURNE其他文献
SAMUEL A SHELBURNE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SAMUEL A SHELBURNE', 18)}}的其他基金
Role of β-lactamase encoding gene amplification in the development of non-carbapenemase producing, carbapenem-resistant Enterobacteriaceae
β-内酰胺酶编码基因扩增在产生非碳青霉烯酶、耐碳青霉烯肠杆菌科细菌中的作用
- 批准号:
10373951 - 财政年份:2021
- 资助金额:
$ 31.6万 - 项目类别:
Impact of regulatory cross-talk on the pathophysiology of emergent acapsular group A streptococcus
监管串扰对新出现的无荚膜 A 族链球菌病理生理学的影响
- 批准号:
10301505 - 财政年份:2021
- 资助金额:
$ 31.6万 - 项目类别:
Impact of regulatory cross-talk on the pathophysiology of emergent acapsular group A streptococcus
监管串扰对新出现的无荚膜 A 族链球菌病理生理学的影响
- 批准号:
10449272 - 财政年份:2021
- 资助金额:
$ 31.6万 - 项目类别:
Project 2: Leveraging Metagenomics of the Microbiome to predict colonization/infection by antimicrobial-resistant pathogens
项目 2:利用微生物组的宏基因组学来预测耐药病原体的定植/感染
- 批准号:
10226288 - 财政年份:2020
- 资助金额:
$ 31.6万 - 项目类别:
Project 2: Leveraging Metagenomics of the Microbiome to predict colonization/infection by antimicrobial-resistant pathogens
项目 2:利用微生物组的宏基因组学来预测耐药病原体的定植/感染
- 批准号:
10614694 - 财政年份:2020
- 资助金额:
$ 31.6万 - 项目类别:
Project 2: Leveraging Metagenomics of the Microbiome to predict colonization/infection by antimicrobial-resistant pathogens
项目 2:利用微生物组的宏基因组学来预测耐药病原体的定植/感染
- 批准号:
10024960 - 财政年份:2020
- 资助金额:
$ 31.6万 - 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
- 批准号:
8300803 - 财政年份:2011
- 资助金额:
$ 31.6万 - 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
- 批准号:
8107818 - 财政年份:2011
- 资助金额:
$ 31.6万 - 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
- 批准号:
8479310 - 财政年份:2011
- 资助金额:
$ 31.6万 - 项目类别:
Contribution of catabolite control protein A to group A streptococcal virulence
分解代谢物控制蛋白 A 对 A 组链球菌毒力的贡献
- 批准号:
8871663 - 财政年份:2011
- 资助金额:
$ 31.6万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 31.6万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 31.6万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 31.6万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 31.6万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 31.6万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 31.6万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 31.6万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 31.6万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 31.6万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 31.6万 - 项目类别:
Research Grant